The Genomic Landscape of Childhood and Adolescent Melanoma

Despite remarkable advances in the genomic characterization of adult melanoma, the molecular pathogenesis of pediatric melanoma remains largely unknown. We analyzed 15 conventional melanomas (CMs), 3 melanomas arising in congenital nevi (CNMs), and 5 spitzoid melanomas (SMs), using various platforms, including whole genome or exome sequencing, the molecular inversion probe assay, and/or targeted sequencing. CMs demonstrated a high burden of somatic single-nucleotide variations (SNVs), with each case containing a TERT promoter (TERT-p) mutation, 13/15 containing an activating BRAF V600 mutation, and >80% of the identified SNVs consistent with UV damage. In contrast, the three CNMs contained an activating NRAS Q61 mutation and no TERT-p mutations. SMs were characterized by chromosomal rearrangements resulting in activated kinase signaling in 40%, and an absence of TERT-p mutations, except for the one SM that succumbed to hematogenous metastasis. We conclude that pediatric CM has a very similar UV-induced mutational spectrum to that found in the adult counterpart, emphasizing the need to promote sun protection practices in early life and to improve access to therapeutic agents being explored in adults in young patients. In contrast, the pathogenesis of CNM appears to be distinct. TERT-p mutations may identify the rare subset of spitzoid melanocytic lesions prone to disseminate.

[1]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[2]  P. Leboit Pathology and genetics of skin tumours , 2006 .

[3]  D. Pinkel,et al.  Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. , 2007, The Journal of investigative dermatology.

[4]  S. Egyházi,et al.  High frequency of p16(INK4A) promoter methylation in NRAS-mutated cutaneous melanoma. , 2010, The Journal of investigative dermatology.

[5]  A. Sarasin,et al.  The role of UV induced lesions in skin carcinogenesis: an overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. , 2005, Mutation research.

[6]  C. Milagre,et al.  Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression , 2011, Pigment cell & melanoma research.

[7]  D. Pinkel,et al.  MC1R germline variants confer risk for BRAF-mutant melanoma. , 2006, Science.

[8]  A. Hauschild,et al.  Melanoma risk in congenital melanocytic naevi: a systematic review , 2006, The British journal of dermatology.

[9]  W. McWhirter,et al.  Risk factors for childhood melanoma in Queensland, Australia , 1997, International journal of cancer.

[10]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[11]  B. Bett Large or multiple congenital melanocytic nevi: occurrence of cutaneous melanoma in 1008 persons. , 2005, Journal of the American Academy of Dermatology.

[12]  A. Marghoob,et al.  Large Congenital Melanocytic Nevi and the Risk for Development of Malignant Melanoma and Neurocutaneous Melanocytosis , 2000, Pediatrics.

[13]  R. Wood,et al.  DNA polymerases and cancer , 2011, Nature Reviews Cancer.

[14]  M. Mihm,et al.  Childhood melanoma: a clinicopathological study of 22 cases , 1997, Melanoma research.

[15]  K. Gow,et al.  Melanoma in children and adolescents. , 2007, Surgical oncology.

[16]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[17]  Jenine K. Harris,et al.  Incidence of Childhood and Adolescent Melanoma in the United States: 1973–2009 , 2013, Pediatrics.

[18]  T. Flotte,et al.  Cutaneous melanoma and atypical spitz tumors in childhood , 1995, Cancer.

[19]  S. Swetter,et al.  Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, Adolescents and Young Adults—The Stanford Experience 1995–2008 , 2010, Pediatric dermatology.

[20]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[21]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[22]  V. Prieto,et al.  Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool , 2009, Journal of cutaneous pathology.

[23]  D. Lazovich,et al.  Germline melanoma susceptibility and prognostic genes: a review of the literature. , 2012, Journal of the American Academy of Dermatology.

[24]  Li Ding,et al.  C11ORF95-RELA FUSIONS DRIVE ONCOGENIC NF-KB SIGNALING IN EPENDYMOMA. , 2014 .

[25]  P. Hanawalt,et al.  Transcription-coupled DNA repair: two decades of progress and surprises , 2008, Nature Reviews Molecular Cell Biology.

[26]  Matthew W. Wilson,et al.  A Novel Retinoblastoma Therapy from Genomic and Epigenetic Analyses , 2011, Nature.

[27]  F. Sera,et al.  MC1R variants, melanoma and red hair color phenotype: A meta‐analysis , 2008, International journal of cancer.

[28]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[29]  T. Fennell,et al.  Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.

[30]  S. Purcell Melanoma and Melanocytic Tumors of Uncertain Malignant Potential in Children, Adolescents and Young Adults—The Stanford Experience 1995–2008 , 2011 .

[31]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .

[32]  D. Schadendorf,et al.  Genetic and morphologic features for melanoma classification , 2010, Pigment cell & melanoma research.

[33]  N. Sebire,et al.  Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRAS , 2013, The Journal of investigative dermatology.

[34]  T. Fears,et al.  Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology and end results database. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Iwei Yeh,et al.  Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy , 2013, Pigment cell & melanoma research.

[36]  J. Choi,et al.  Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta‐analysis , 2011, The British journal of dermatology.

[37]  Daniel Pinkel,et al.  Classifying melanocytic tumors based on DNA copy number changes. , 2003, The American journal of pathology.

[38]  R. Marais,et al.  Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.

[39]  J. Bartek,et al.  The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis. , 1996, Cancer research.

[40]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[41]  G. Pfeifer,et al.  Mutations induced by ultraviolet light. , 2005, Mutation research.

[42]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[43]  D. Elder,et al.  Outcomes of Atypical Spitz Tumors With Chromosomal Copy Number Aberrations and Conventional Melanomas in Children , 2013, The American journal of surgical pathology.

[44]  Li Ding,et al.  C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma , 2014, Nature.

[45]  Iwei Yeh,et al.  Kinase fusions are frequent in Spitz tumours and spitzoid melanomas , 2014, Nature Communications.

[46]  D. Pinkel,et al.  Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. , 1998, Cancer research.

[47]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[48]  Claus Garbe,et al.  Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. , 2008, Advances in experimental medicine and biology.